- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: compound 122 [WO2013092791A1] | GLPG-1205
Compound class: Synthetic organic
Comment: GLPG1205 is an investigational, orally bioavailable GPR84 antagonist that was being developed by Galapagos. The chemical structure is claimed as compound 122 in patent WO2013092791A1, for the treatment of inflammatory disorders . Galapagos cut GLPG1205 (for idiopathic pulmonary fibrosis, IPF) from their development pipeline in a cost-cutting exercise in the first half of 2021. Their chitinase inhibitor, GLPG4617 (structure undisclosed), will be taken forward into a phase 2 study for IPF.
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
1. Labeguere FG, Nwesome GJR, Alvey LJ, Saniere LRM, Fletcher SR. (2013)
Novel dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders.
Patent number: WO2013092791A1. Assignee: Galapagos Nv. Priority date: 22/12/2011. Publication date: 27/06/2013.
2. Sundqvist M, Christenson K, Holdfeldt A, Gabl M, Mårtensson J, Björkman L, Dieckmann R, Dahlgren C, Forsman H. (2018)
Similarities and differences between the responses induced in human phagocytes through activation of the medium chain fatty acid receptor GPR84 and the short chain fatty acid receptor FFA2R.
Biochim Biophys Acta Mol Cell Res, 1865 (5): 695-708. [PMID:29477577]